Alpha Cognition Inc (ACOG) Stock Score, Valuation & Financial Research
Alpha Cognition Inc is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 38/100.
Quick answer for ACOG
Alpha Cognition Inc currently has a Wall Street Score of 38/100. The stored market price is $8.9. Its financial score is 46/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Alpha Cognition Inc does
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
ACOG financial snapshot
- Wall Street Score:
- 38/100
- Current price:
- $8.9
- Market capitalization:
- $138.2M
- Revenue:
- $15.3M
- Net income:
- $-23.4M
- Free cash flow:
- $-20.7M
- Cash:
- $41.4M
- Total debt:
- $0
- EPS:
- -1.09
- Financial score:
- 46/100
- Valuation score:
- 0/100
- Revenue score:
- 0/100
What stands out
- Reported year-over-year revenue growth is +0.5%.
- Free cash flow is $-20.7M, showing cash burn in the current stored period.
- The balance sheet shows $41.4M of cash versus $0 of total debt, leaving more cash than debt.
- The current research record carries a missing revenue history warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 46/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research ACOG
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.